The Senate Committee on Health, Education, Labor and Pensions (HELP) today questioned Heidi Overton, M.D., Ph.D., Trump’s pick for FDA commissioner, in a hearing marked by tightrope-walking on issues like vaccines, abortions, flavored vapes and whether or not President Donald Trump is capable of being wrong.

The FDA has greenlighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel cancer drug from a Korean company to secure FDA approval.

GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory body ruled.

Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established biologics production base for its lead antibody drug candidate.

Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness.

The Ozempic and Wegovy maker’s CEO said he’s open to a direct listing of Novo’s shares on the New York Stock Exchange, but no such transition is currently underway.